加科思/艾力斯 KRAS G12C抑制剂获批上市

动脉网
22 May

加科思与艾力斯开发的KRAS G12C抑制剂戈来雷塞在国内获批上市,用于治疗KRAS G12C突变的非小细胞肺癌,该药还曾在胰腺癌和结直肠癌中被纳入突破性治疗品种名单,并在美国获得FDA授予的胰腺癌适应症孤儿药资格认定。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10